In 16 obese IBD patients, GLP-1 drugs produced 6.2% weight loss at 6 months without triggering disease flares, though the sample was very small.
No IBD flaresNone of the 16 IBD patients experienced a disease flare while taking GLP-1 drugs for obesity
What the researchers found
Sixteen obese patients with IBD (9 Crohn's disease, 7 ulcerative colitis) received semaglutide 1.0 mg or liraglutide 3.0 mg for obesity. Their median starting BMI was 35.
At 6 months, median weight change was -6.2%. 58.3% (7 of 12 evaluable patients) achieved at least 5% weight loss. IBD activity scores showed no significant changes during follow-up, meaning the drugs did not trigger disease flares.
Side effects were mild. Nausea was the most common at 13.3%. One patient discontinued due to diarrhea. No serious adverse events were reported.
Why it matters
Obesity is common in IBD patients and worsens their disease outcomes. But GLP-1 drugs have not been studied in IBD patients, raising concerns that GI side effects could worsen IBD symptoms or trigger flares. This small study provides the first evidence that GLP-1 drugs are safe and effective for weight loss in this population.
The numbers in context
- 16 patients (9 Crohn's, 7 ulcerative colitis)
- Median baseline BMI: 35
- Median weight change at 6 months: -6.2%
- 5% weight loss achieved: 58.3% (7/12)
- Nausea: 13.3%
- 1 withdrawal due to diarrhea
- IBD activity: no significant changes
How the study worked
Retrospective case series of consecutive IBD patients who received GLP-1 drugs (semaglutide 1.0 mg or liraglutide 3.0 mg) for obesity between 2019 and 2021. The coprimary endpoints were percentage weight change at 6 months and proportion achieving 5% or more weight loss. IBD activity and safety were monitored.
Who was studied
16 obese adults with inflammatory bowel disease (9 Crohn's, 7 ulcerative colitis) in Spain
What this study cannot tell us
This is a very small retrospective case series with only 16 patients and no control group. The follow-up was only 6 months. IBD activity was assessed using clinical scores, not endoscopy or biomarkers, which could miss subclinical inflammation. The study cannot distinguish between semaglutide and liraglutide effects. Publication bias may favor reporting positive results.
How to read the evidence
Rated preliminary: very small retrospective case series with only 16 patients and 6 months follow-up. Important as first data in this population.
When this study was published
Published in 2024. First published evidence on GLP-1 drug safety in inflammatory bowel disease patients.
The bigger picture
GLP-1 drugs have not been studied in IBD patients, creating uncertainty about whether their GI side effects could worsen IBD. This small but important case series provides early reassurance.
Questions still open
- Would a larger study confirm the safety in IBD patients?
- Do GLP-1 drugs affect IBD inflammatory markers?
Common questions
Can IBD patients take Ozempic?
Do GLP-1 drug GI side effects worsen IBD?
Read the original research
Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.
Revista espanola de enfermedades digestivas, 116(9), 478-483
Citation
Ramos Belinchón, Clara; Martínez-Lozano, Helena; Serrano Moreno, Clara; Hernández Castillo, Diego; Lois Chicharro, Pablo; Ferreira Ocampo, Pablo; Marín-Jiménez, Ignacio; Bretón Lesmes, Irene; Menchén, Luis. (2024). Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease.. Revista espanola de enfermedades digestivas, 116(9), 478-483. https://doi.org/10.17235/reed.2024.10305/2024